Log In
Print this Print this

RG7813, RO6895882

  Manage Alerts
Collapse Summary General Information
Company Roche
DescriptionImmunocytokine combining an engineered cytokine (IL-2v) with an antibody against carcinoembryonic antigen (CEA)
Molecular Target Carcinoembryonic antigen (CEA)
Mechanism of Action 
Therapeutic ModalityBiologic
Latest Stage of DevelopmentPhase I
Standard IndicationSolid tumors
Indication DetailsTreat solid tumors
Regulatory Designation

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
 Deals Details
Get a free BioCentury trial today